1
|
Yang X, Tian X, Sun N, Hu B, Shen Z, Hu X, Jin L. Geometry-Constrained N, N, O-Nickel Catalyzed α-Alkylation of Unactivated Amides via a Borrowing Hydrogen Strategy. Organometallics 2022. [DOI: 10.1021/acs.organomet.2c00470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Xue Yang
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
| | - Xiaoyu Tian
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
| | - Nan Sun
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
| | - Baoxiang Hu
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
| | - Zhenlu Shen
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
| | - Xinquan Hu
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
| | - Liqun Jin
- College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310032, P. R. China
- State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, The Chinese Academy of Sciences, Lanzhou 730000, P. R. China
| |
Collapse
|
2
|
McCoull W, Augustin M, Blake C, Ertan A, Kilgour E, Krapp S, Moore JE, Newcombe NJ, Packer MJ, Rees A, Revill J, Scott JS, Selmi N, Gerhardt S, Ogg DJ, Steinbacher S, Whittamore PRO. Identification and optimisation of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). MEDCHEMCOMM 2014. [DOI: 10.1039/c3md00234a] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
3
|
Scott JS, Goldberg FW, Turnbull AV. Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). J Med Chem 2013; 57:4466-86. [DOI: 10.1021/jm4014746] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- James S. Scott
- AstraZeneca Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Frederick W. Goldberg
- AstraZeneca Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| | - Andrew V. Turnbull
- AstraZeneca Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K
| |
Collapse
|
4
|
Böhme T, Engel CK, Farjot G, Güssregen S, Haack T, Tschank G, Ritter K. 1,1-Dioxo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes. Bioorg Med Chem Lett 2013; 23:4685-91. [PMID: 23845218 DOI: 10.1016/j.bmcl.2013.05.102] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2013] [Revised: 05/29/2013] [Accepted: 05/31/2013] [Indexed: 11/19/2022]
Abstract
Racemic cis-1,1-dioxo-5,6-dihydro-[4,1,2]oxathiazine derivative 4a was isolated as an impurity in a sample of a hit from a HTS campaign on 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). After separation by chiral chromatography the 4a-S, 8a-R enantiomer of compound 4a was identified as the true, potent enzyme inhibitor. The cocrystal structure of 4a with human and murine 11ß-HSD1 revealed the unique binding mode of the oxathiazine series. SAR elucidation and optimization in regard to metabolic stability led to monocyclic tetramethyloxathiazines as exemplified by compound 21g.
Collapse
Affiliation(s)
- Thomas Böhme
- Sanofi Deutschland GmbH, R&D, Industriepark Höchst, 65926 Frankfurt am Main, Germany
| | | | | | | | | | | | | |
Collapse
|
5
|
Wanka L, Iqbal K, Schreiner PR. The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev 2013; 113:3516-604. [PMID: 23432396 PMCID: PMC3650105 DOI: 10.1021/cr100264t] [Citation(s) in RCA: 429] [Impact Index Per Article: 39.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Lukas Wanka
- Institute of Organic Chemistry, Justus-Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; Fax +49(641)9934309
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
| | - Khalid Iqbal
- Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314-6399, USA
| | - Peter R. Schreiner
- Institute of Organic Chemistry, Justus-Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; Fax +49(641)9934309
| |
Collapse
|
6
|
Discovery of SAR184841, a potent and long-lasting inhibitor of 11β-hydroxysteroid dehydrogenase type 1, active in a physiopathological animal model of T2D. Bioorg Med Chem Lett 2013; 23:2414-21. [DOI: 10.1016/j.bmcl.2013.02.018] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Revised: 01/31/2013] [Accepted: 02/03/2013] [Indexed: 01/16/2023]
|
7
|
Wu SC, Yoon D, Chin J, van Kirk K, Seethala R, Golla R, He B, Harrity T, Kunselman LK, Morgan NN, Ponticiello RP, Taylor JR, Zebo R, Harper TW, Li W, Wang M, Zhang L, Sleczka BG, Nayeem A, Sheriff S, Camac DM, Morin PE, Everlof JG, Li YX, Ferraro CA, Kieltyka K, Shou W, Vath MB, Zvyaga TA, Gordon DA, Robl JA. Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1). Bioorg Med Chem Lett 2011; 21:6693-8. [PMID: 21983444 DOI: 10.1016/j.bmcl.2011.09.058] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Revised: 09/14/2011] [Accepted: 09/15/2011] [Indexed: 11/30/2022]
Abstract
Derived from the HTS hit 1, a series of hydroxyisoquinolines was discovered as potent and selective 11β-HSD1 inhibitors with good cross species activity. Optimization of substituents at the 1 and 4 positions of the isoquinoline group in addition to the core modifications, with a special focus on enhancing metabolic stability and aqueous solubility, resulted in the identification of several compounds as potent advanced leads.
Collapse
Affiliation(s)
- Shung C Wu
- Bristol-Myers Squibb Research & Development, PO Box 5400, Hopewell, NJ 08534-5400, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Wan ZK, Chenail E, Li HQ, Kendall C, Wang Y, Gingras S, Xiang J, Massefski WW, Mansour TS, Saiah E. Synthesis of Potent and Orally Efficacious 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor HSD-016. J Org Chem 2011; 76:7048-55. [DOI: 10.1021/jo200958a] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Zhao-Kui Wan
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Eva Chenail
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Huan-Qiu Li
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Christopher Kendall
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Youchu, Wang
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Stéphane Gingras
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Jason Xiang
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Walter W. Massefski
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Tarek, S. Mansour
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Eddine Saiah
- Pfizer Worldwide Research and Development, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| |
Collapse
|
9
|
Venier O, Pascal C, Braun A, Namane C, Mougenot P, Crespin O, Pacquet F, Mougenot C, Monseau C, Onofri B, Dadji-Faïhun R, Leger C, Ben-Hassine M, Van-Pham T, Ragot JL, Philippo C, Güssregen S, Engel C, Farjot G, Noah L, Maniani K, Nicolaï E. Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1. Bioorg Med Chem Lett 2011; 21:2244-51. [PMID: 21439819 DOI: 10.1016/j.bmcl.2011.02.111] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Revised: 02/25/2011] [Accepted: 02/27/2011] [Indexed: 11/26/2022]
Abstract
A High Throughput Screening campaign allowed the identification of a novel class of ureas as 11β-HSD1 inhibitors. Rational chemical optimization provided potent and selective inhibitors of both human and murine 11β-HSD1 with an appropriate ADME profile and ex vivo activity in target tissues.
Collapse
Affiliation(s)
- Olivier Venier
- Sanofi-aventis R&D, 1 Avenue Pierre Brossolette, 91385 Chilly-Mazarin, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Sun D, Wang Z, Caille S, DeGraffenreid M, Gonzalez-Lopez de Turiso F, Hungate R, Jaen JC, Jiang B, Julian LD, Kelly R, McMinn DL, Kaizerman J, Rew Y, Sudom A, Tu H, Ursu S, Walker N, Willcockson M, Yan X, Ye Q, Powers JP. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2010; 21:405-10. [PMID: 21093258 DOI: 10.1016/j.bmcl.2010.10.129] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2010] [Revised: 10/23/2010] [Accepted: 10/26/2010] [Indexed: 11/20/2022]
Abstract
The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11β-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models.
Collapse
Affiliation(s)
- Daqing Sun
- Amgen Inc, 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Yan X, Wang Z, Sudom A, Cardozo M, DeGraffenreid M, Di Y, Fan P, He X, Jaen JC, Labelle M, Liu J, Ma J, McMinn D, Miao S, Sun D, Tang L, Tu H, Ursu S, Walker N, Ye Q, Powers JP. The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2010; 20:7071-5. [PMID: 20971000 DOI: 10.1016/j.bmcl.2010.09.097] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2010] [Revised: 09/15/2010] [Accepted: 09/16/2010] [Indexed: 10/19/2022]
Abstract
In this communication, human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitory activities of a novel series of diarylsulfones are described. Optimization of this series resulted in several highly potent 11β-HSD1 inhibitors with excellent pharmacokinetic (PK) properties. Compound (S)-25 showed excellent efficacy in a non-human primate ex vivo pharmacodynamic model.
Collapse
Affiliation(s)
- Xuelei Yan
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
|
13
|
Wan ZK, Chenail E, Xiang J, Li HQ, Ipek M, Bard J, Svenson K, Mansour TS, Xu X, Tian X, Suri V, Hahm S, Xing Y, Johnson CE, Li X, Qadri A, Panza D, Perreault M, Tobin JF, Saiah E. Efficacious 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model. J Med Chem 2009; 52:5449-61. [DOI: 10.1021/jm900639u] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
| | | | | | | | | | | | | | | | - Xin Xu
- Drug Safety and Metabolism
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Siu M, Johnson TO, Wang Y, Nair SK, Taylor WD, Cripps SJ, Matthews JJ, Edwards MP, Pauly TA, Ermolieff J, Castro A, Hosea NA, LaPaglia A, Fanjul AN, Vogel JE. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg Med Chem Lett 2009; 19:3493-7. [DOI: 10.1016/j.bmcl.2009.05.011] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2009] [Revised: 05/03/2009] [Accepted: 05/04/2009] [Indexed: 11/24/2022]
|
15
|
Sun D, Wang Z, Cardozo M, Choi R, DeGraffenreid M, Di Y, He X, Jaen JC, Labelle M, Liu J, Ma J, Miao S, Sudom A, Tang L, Tu H, Ursu S, Walker N, Yan X, Ye Q, Powers JP. Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorg Med Chem Lett 2009; 19:1522-7. [DOI: 10.1016/j.bmcl.2008.12.114] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2008] [Revised: 12/23/2008] [Accepted: 12/31/2008] [Indexed: 11/15/2022]
|
16
|
Sun D, Wang Z, Di Y, Jaen JC, Labelle M, Ma J, Miao S, Sudom A, Tang L, Tomooka CS, Tu H, Ursu S, Walker N, Yan X, Ye Q, Powers JP. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett 2008; 18:3513-6. [PMID: 18511278 DOI: 10.1016/j.bmcl.2008.05.025] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2008] [Revised: 05/02/2008] [Accepted: 05/07/2008] [Indexed: 10/22/2022]
Abstract
High-throughput screening of a small-molecule compound library resulted in the identification of a series of arylsulfonylpiperazines that are potent and selective inhibitors of human 11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1). Optimization of the initial lead resulted in the discovery of compound (R)-45 (11beta-HSD1 IC(50)=3nM).
Collapse
Affiliation(s)
- Daqing Sun
- Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Johansson L, Fotsch C, Bartberger MD, Castro VM, Chen M, Emery M, Gustafsson S, Hale C, Hickman D, Homan E, Jordan SR, Komorowski R, Li A, McRae K, Moniz G, Matsumoto G, Orihuela C, Palm G, Veniant M, Wang M, Williams M, Zhang J. 2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Enzyme−Ligand Co-Crystal Structure and Demonstration of Pharmacodynamic Effects in C57Bl/6 Mice. J Med Chem 2008; 51:2933-43. [DOI: 10.1021/jm701551j] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Lars Johansson
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Christopher Fotsch
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Michael D. Bartberger
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Victor M. Castro
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Michelle Chen
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Maurice Emery
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Sonja Gustafsson
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Clarence Hale
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Dean Hickman
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Evert Homan
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Steven R. Jordan
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Renee Komorowski
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Aiwen Li
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Kenneth McRae
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - George Moniz
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Guy Matsumoto
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Carlos Orihuela
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Gunnar Palm
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Murielle Veniant
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Minghan Wang
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Meredith Williams
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Jiandong Zhang
- Biovitrum AB, SE-112 76 Stockholm, Sweden, and Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| |
Collapse
|
18
|
Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 2008; 17:481-96. [DOI: 10.1517/13543784.17.4.481] [Citation(s) in RCA: 77] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
19
|
Yuan C, St. Jean DJ, Liu Q, Cai L, Li A, Han N, Moniz G, Askew B, Hungate RW, Johansson L, Tedenborg L, Pyring D, Williams M, Hale C, Chen M, Cupples R, Zhang J, Jordan S, Bartberger MD, Sun Y, Emery M, Wang M, Fotsch C. The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors. Bioorg Med Chem Lett 2007; 17:6056-61. [DOI: 10.1016/j.bmcl.2007.09.070] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2007] [Revised: 09/19/2007] [Accepted: 09/19/2007] [Indexed: 10/22/2022]
|